- AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia (AML)
- Additional abstract on AMX-883 BRAMLIE trial assessing safety, pharmacokinetics, and preliminary efficiency to publish in Blood
Amphista Therapeutics Limited, a clinical-stage biopharmaceutical company focused on the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced new data on its lead therapeutic candidate, AMX-883, has been accepted for oral presentation at American Society of Hematology (ASH) Annual Meeting in New Orleans, December 12–15, 2026. The full abstract is available online: www.hematology.org/Meetings/Annual-Meeting/Abstracts
The data, to be presented by Dr Louise Modis, CEO, suggest BRD9 plays a critical role in acute myeloid leukaemia (AML), maintaining activity of a number of hematopoietic transcription factors. Degradation of BRD9 using AMX-883 restricts these transcription factor programmes, releasing the differentiation block and reducing the frequency of leukemic stem cells.
Presentation details:
- Title: AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation and depletes leukemic stem cells in acute myeloid leukaemia
- Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Cell-Intrinsic and Niche-Mediated Mechanisms of Drug Resistance in AML. December 14, 2026, 10:30 AM – 12:00 PM
- Room: MCCNO – Great Hall BC
- Presentation time: December 14, 2026, 11:45 AM – 12:00 PM
- Publication number: 762
- Submission ID: abs26-9908
The second abstract, due to be published in the ASH Blood Supplement, highlights Amphista’s ongoing AMX-883 BRAMLIE trial1, an open label, multi-part, dose escalation and optimisation study:
- Abstract number: abs26-2088
- Title: A Phase 1, open-label, multi-centre study to assess the safety, pharmacokinetics and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia and high-risk myelodysplastic syndrome and in combination in participants with AML
- Category: 600s – Hematologic Malignancy
- Review category: 616. Acute Myeloid Leukemias: lnvestigational Drug and Cellular Therapies
- Authors: Eytan Stein, Emma Searle, Amir Fathi, Jayastu Senapati, Justin Watts, Victoria Campbell, Jenny O’Nions, Alexander Spira, David Taussig, Paul Player, Giulia Petrone, Anthony Selwyn Stein, Lisa Butler, Patrick Kelly



















